Post-treatment de-phosphorylation of p53 correlates with dasatinib responsiveness in malignant melanoma.

Loss of p53 phosphorylation might be an interesting candidate for a kinetic marker of dasatinib responsiveness in melanoma, pending more comprehensive validation in future studies.